Welcome to LookChem.com Sign In|Join Free
  • or
Chloroform-d (Deuterochloroform, CDCl3) is a deuterated compound that is an isotopologue of chloroform in which the hydrogen atom is replaced with a deuterium. It is a colorless liquid and is 100% isotopically enriched as a Nuclear Magnetic Resonance (NMR) solvent. Chloroform-d is widely employed in high-resolution NMR studies due to its high chemical and isotopic purity.

865-49-6

Post Buying Request

865-49-6 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

865-49-6 Usage

Uses

Used in NMR Spectroscopy:
Chloroform-d is used as a solvent in proton NMR spectroscopy for its high chemical and isotopic purity, which is essential for accurate and reliable results in high-resolution NMR studies.
Used in Organic Synthesis:
Chloroform-d may be used in the synthesis of dichlorofluoromethane-d (DCFM), a compound with potential applications in various industries.
Used in Reagents for Nuclear Magnetic Instruments:
Chloroform-d is used as a reagent for nuclear magnetic instruments, providing a stable and reliable solvent for NMR analysis.
Used in Anaesthetic Applications (Unlabelled Chloroform):
Unlabelled chloroform has been used as an anaesthetic due to its action on the central nervous system. However, it is important to note that this application is for unlabelled chloroform and not specifically for chloroform-d.
Used in Quantitative Infrared Spectral Investigations:
Chloroform-d has been used in quantitative infrared spectral investigations of carbon-deuterium stretching bands in various organic solvents, contributing to the understanding of its chemical properties and behavior.
Used in Raman Difference Spectroscopic Studies:
Mixtures of chloroform-d and liquid chloroform have been used in Raman difference spectroscopic studies to evaluate frequency shifts in the ν1 and ν2 bands of CHCl3 and CDCl3, further enhancing the knowledge of its chemical properties.

Water peak

The position of the water peak in different deuterated reagents is not the same. The water peak of heavy water is about 4.67 ppm. There is a trend that the more water the low field. Chloroform-D is less soluble with water and the water content is low, so its water peak near 1.59 ppm. Deuterated acetone is about 2.8 ppm and the deuterated dimethylsulfoxide has a water peak of about 3.4 ppm. If water is added to deuterated acetone, the water peak will gradually move to a low field and eventually stop at about 4.7 ppm.

Check Digit Verification of cas no

The CAS Registry Mumber 865-49-6 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 8,6 and 5 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 865-49:
(5*8)+(4*6)+(3*5)+(2*4)+(1*9)=96
96 % 10 = 6
So 865-49-6 is a valid CAS Registry Number.
InChI:InChI=1/CHCl3/c2-1(3)4/h1H/i1D

865-49-6 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Alfa Aesar

  • (42270)  Chloroform-d, 100% (Isotopic)   

  • 865-49-6

  • 2each

  • 181.0CNY

  • Detail
  • Alfa Aesar

  • (42270)  Chloroform-d, 100% (Isotopic)   

  • 865-49-6

  • 10each

  • 817.0CNY

  • Detail
  • Alfa Aesar

  • (41388)  Chloroform-d, 100% (Isotopic), contains 0.03% v/v TMS   

  • 865-49-6

  • 5each

  • 455.0CNY

  • Detail
  • Alfa Aesar

  • (41388)  Chloroform-d, 100% (Isotopic), contains 0.03% v/v TMS   

  • 865-49-6

  • 10each

  • 817.0CNY

  • Detail
  • Alfa Aesar

  • (89541)  Chloroform-d, 99.8% (Isotopic)   

  • 865-49-6

  • 50g

  • 368.0CNY

  • Detail
  • Alfa Aesar

  • (89541)  Chloroform-d, 99.8% (Isotopic)   

  • 865-49-6

  • 250g

  • 1729.0CNY

  • Detail
  • Alfa Aesar

  • (41389)  Chloroform-d, 99.8% (Isotopic), contains 0.03% v/v TMS   

  • 865-49-6

  • 25g

  • 227.0CNY

  • Detail
  • Alfa Aesar

  • (41389)  Chloroform-d, 99.8% (Isotopic), contains 0.03% v/v TMS   

  • 865-49-6

  • 25ml

  • 276.0CNY

  • Detail
  • Alfa Aesar

  • (41389)  Chloroform-d, 99.8% (Isotopic), contains 0.03% v/v TMS   

  • 865-49-6

  • 100g

  • 331.0CNY

  • Detail
  • Alfa Aesar

  • (41389)  Chloroform-d, 99.8% (Isotopic), contains 0.03% v/v TMS   

  • 865-49-6

  • *5x100g

  • 1656.0CNY

  • Detail
  • Alfa Aesar

  • (36470)  Chloroform-d, 99.8% (Isotopic), contains 1% v/v TMS   

  • 865-49-6

  • 25g

  • 265.0CNY

  • Detail
  • Alfa Aesar

  • (36470)  Chloroform-d, 99.8% (Isotopic), contains 1% v/v TMS   

  • 865-49-6

  • 100g

  • 529.0CNY

  • Detail

865-49-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name deuterated chloroform

1.2 Other means of identification

Product number -
Other names Chloroform,deutero

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:865-49-6 SDS

865-49-6Synthetic route

(CD(CH3)2CH2)3SnOC3H7-i

(CD(CH3)2CH2)3SnOC3H7-i

Bromotrichloromethane
75-62-7

Bromotrichloromethane

A

chloroform-d1
865-49-6

chloroform-d1

B

chloroform
67-66-3

chloroform

C

1,1,1-trichloro-3,3-dimethyl-3-bromopropane
23153-21-1

1,1,1-trichloro-3,3-dimethyl-3-bromopropane

D

isopropyl alcohol
67-63-0

isopropyl alcohol

E

acetone
67-64-1

acetone

Conditions
ConditionsYield
byproducts: CHCl3; Irradiation (UV/VIS); 70°C;A n/a
B n/a
C 10%
D 35%
E 60%
byproducts: CHCl3; Irradiation (UV/VIS); 70°C;A n/a
B n/a
C 10%
D 35%
E 60%
(C4H9)3SnOC6H10D

(C4H9)3SnOC6H10D

Bromotrichloromethane
75-62-7

Bromotrichloromethane

A

chloroform-d1
865-49-6

chloroform-d1

B

3-bromo-1,1,1-trichloro-pentane
101774-42-9

3-bromo-1,1,1-trichloro-pentane

C

chloroform
67-66-3

chloroform

D

cyclohexanone
108-94-1

cyclohexanone

E

cyclohexanol
108-93-0

cyclohexanol

Conditions
ConditionsYield
38% yield of CHCl3 and CDCl3;A n/a
B 18%
C n/a
D 14%
E 38%
38% yield of CHCl3 and CDCl3;A n/a
B 18%
C n/a
D 14%
E 38%
tetrachloromethane
56-23-5

tetrachloromethane

A

chloroform-d1
865-49-6

chloroform-d1

B

chloroform
67-66-3

chloroform

Conditions
ConditionsYield
With d8-isopropanol In water at 25℃; pH=7; Kinetics;A 33%
B 13%
2,2,2-trichloro-O,O'-dideuterio-ethane-1,1-diol
19220-07-6

2,2,2-trichloro-O,O'-dideuterio-ethane-1,1-diol

chloroform-d1
865-49-6

chloroform-d1

Conditions
ConditionsYield
With deuteriated sodium hydroxide; water-d2
chloroform
67-66-3

chloroform

chloroform-d1
865-49-6

chloroform-d1

Conditions
ConditionsYield
With water-d2; potassium carbonate at 100 - 105℃;
With deuteriated sodium hydroxide In water-d2 at 26℃; Rate constant; Product distribution; Kinetics;
With cis-[RuCl2(1,4-bis(diphenylphosphine)butane)(2,2′-bipyridine)]; water-d2; potassium hydroxide at 20℃; for 3h; Catalytic behavior; Reagent/catalyst; Time;
2,2,2-trichloroacetophenone
2902-69-4

2,2,2-trichloroacetophenone

chloroform-d1
865-49-6

chloroform-d1

Conditions
ConditionsYield
With deuteriated sodium hydroxide; water-d2 at -78℃;
chloral
75-87-6

chloral

chloroform-d1
865-49-6

chloroform-d1

Conditions
ConditionsYield
With water-d2; calcium oxide
Trichloroacetyl chloride
76-02-8

Trichloroacetyl chloride

chloroform-d1
865-49-6

chloroform-d1

Conditions
ConditionsYield
With water-d2; sodium carbonate; calcium carbonate
trichloromethyltrimethylsilane
5936-98-1

trichloromethyltrimethylsilane

A

chloroform-d1
865-49-6

chloroform-d1

B

chloroform
67-66-3

chloroform

Conditions
ConditionsYield
With methanol; deuteromethanol; sodium methylate at 21℃; Product distribution; value of product isotope effect;
toluene-d3
1124-18-1

toluene-d3

tert-butyl trichloroperacetate
69093-96-5

tert-butyl trichloroperacetate

chloroform-d1
865-49-6

chloroform-d1

Conditions
ConditionsYield
In tetrachloromethane at 80℃; for 12h; Rate constant; relative rate constants, presence of subst. toluenes or cyclohexane;
Cyclohexane-d12
1735-17-7

Cyclohexane-d12

tert-butyl trichloroperacetate
69093-96-5

tert-butyl trichloroperacetate

chloroform-d1
865-49-6

chloroform-d1

Conditions
ConditionsYield
In tetrachloromethane at 80℃; for 12h; Rate constant; relative rate constants, presence of cyclohexane;
calcium trichloroacetate

calcium trichloroacetate

chloroform-d1
865-49-6

chloroform-d1

Conditions
ConditionsYield
With deuteriated sodium hydroxide; water-d2
chloroform
67-66-3

chloroform

chlorine
7782-50-5

chlorine

deuterium chloride

deuterium chloride

chloroform-d1
865-49-6

chloroform-d1

Conditions
ConditionsYield
at 85℃; UV-Licht.Irradiation;
chloroform
67-66-3

chloroform

D2O

D2O

K2CO3

K2CO3

chloroform-d1
865-49-6

chloroform-d1

Conditions
ConditionsYield
at 100 - 105℃;
2,2,2-trichloro-O,O'-dideuterio-ethane-1,1-diol
19220-07-6

2,2,2-trichloro-O,O'-dideuterio-ethane-1,1-diol

NaOD

NaOD

D2O

D2O

chloroform-d1
865-49-6

chloroform-d1

chloroform-d1
865-49-6

chloroform-d1

Ru(CO)4(P(CH3)2C6H5)
157808-52-1, 31447-09-3

Ru(CO)4(P(CH3)2C6H5)

Ru2(CO)4[P(CH3)2C6H5]2Cl2
157699-27-9

Ru2(CO)4[P(CH3)2C6H5]2Cl2

Conditions
ConditionsYield
With CHCl3 In chloroform under N2; light yellow soln. Ru-complex/CHCl3 stirred at 45°C for 2.5 h (soln. turned bright yellow); evapn., column chromy. (Kieselgel 60, hexane/CH2Cl2 (20/1));100%
chloroform-d1
865-49-6

chloroform-d1

(2-(diphenylphosphanyl)benzaldehyde benzoylhydrazone)PdMe(Cl)
422313-58-4

(2-(diphenylphosphanyl)benzaldehyde benzoylhydrazone)PdMe(Cl)

carbon monoxide
201230-82-2

carbon monoxide

[((2-(diphenylphosphanyl)benzaldehyde benzoylhydrazone)PdCOMe(Cl)]*CDCl3

[((2-(diphenylphosphanyl)benzaldehyde benzoylhydrazone)PdCOMe(Cl)]*CDCl3

Conditions
ConditionsYield
In chloroform-d1 sapphire NMR tube, 30 atm., stirring at 20 °C for 20 h; soln. was filtered through Celite, Et2O was added, ppt. was filtered off, washed with Et2O, slow diffusion of Et2O into CDCl3 soln. at -20 °C, elem. anal.;99%
chloroform-d1
865-49-6

chloroform-d1

[RhH(O2)((C4H9)2PCH2CH2C(CH2)CH2CH2P(C4H9)2)]
181188-40-9

[RhH(O2)((C4H9)2PCH2CH2C(CH2)CH2CH2P(C4H9)2)]

ClRh((CH3)3C)2PCH2CH2C(CH2)CH2CH2P(C(CH3)3)2
72051-17-3

ClRh((CH3)3C)2PCH2CH2C(CH2)CH2CH2P(C(CH3)3)2

Conditions
ConditionsYield
In chloroform-d1 1 d;99%
chloroform-d1
865-49-6

chloroform-d1

ortho-B10H10C(Pt-Bu2)C(PEt2)
1021604-41-0

ortho-B10H10C(Pt-Bu2)C(PEt2)

nido-B10H10C(PDt-Bu2)C(PClEt2)

nido-B10H10C(PDt-Bu2)C(PClEt2)

Conditions
ConditionsYield
In chloroform-d1 standing in CDCl3 for 28 h; detected by NMR spectra;99%
chloroform-d1
865-49-6

chloroform-d1

(IPr)2NiCl
1220982-83-1

(IPr)2NiCl

trans-(1,3-bis(2,6-diisopropylphenyl)imidazolin-2-yliden)2NiCl2

trans-(1,3-bis(2,6-diisopropylphenyl)imidazolin-2-yliden)2NiCl2

Conditions
ConditionsYield
In chloroform-d199%
chloroform-d1
865-49-6

chloroform-d1

[Ru(hydridotris(pyrazol-1-yl)borato)2(tetrahydrothiophene)2]

[Ru(hydridotris(pyrazol-1-yl)borato)2(tetrahydrothiophene)2]

[Ru(hydridotris(pyrazol-1-yl)borato)2] * CDCl3

[Ru(hydridotris(pyrazol-1-yl)borato)2] * CDCl3

Conditions
ConditionsYield
In chloroform-d1 N2-atmosphere; standing for 1 week; pptn. on partial evapn.; elem. anal.;97%
chloroform-d1
865-49-6

chloroform-d1

di(C6H3(NMe2)2)stannylene

di(C6H3(NMe2)2)stannylene

SnCl(SiDCl2)(C6H3(N(CH3)2)2)2

SnCl(SiDCl2)(C6H3(N(CH3)2)2)2

Conditions
ConditionsYield
In diethyl ether; chloroform-d1 under Ar atm. using Schlenk techniques; excess CDCl3 added to soln. of Sn(C6H3(NMe)2)2 in Et2O at 25°C; soln. stirred for 2 h; solvent removed (vac.); ppt. treated (hexane); kept at -30°C for 12 h;96%
dichloro bis(acetonitrile) palladium(II)
21264-30-2, 90243-59-7, 14592-56-4

dichloro bis(acetonitrile) palladium(II)

chloroform-d1
865-49-6

chloroform-d1

sulfur dioxide
7446-09-5

sulfur dioxide

oxygen
80937-33-3

oxygen

4,4',4-tri-tert-butyl-2,2':6',2-terpyridine

4,4',4-tri-tert-butyl-2,2':6',2-terpyridine

(4,4',4''-tri(tert-butyl)-2,2':6',2''-terpyridine)(S-sulfito)palladium(II)
484652-13-3, 484652-19-9

(4,4',4''-tri(tert-butyl)-2,2':6',2''-terpyridine)(S-sulfito)palladium(II)

(4,4',4''-tri(tert-butyl)-2,2':6',2''-terpyridine)chloropalladium(II) chloride*2.5(CDCl3)

(4,4',4''-tri(tert-butyl)-2,2':6',2''-terpyridine)chloropalladium(II) chloride*2.5(CDCl3)

Conditions
ConditionsYield
In acetonitrile byproducts: acetamide; Pd complex dissolved in MeCN at room temp.; stirred for 10 min; O2-SO2 bubbled into the soln.; solid ligand (0.26 equiv.) added; dissolved over 10 min; remaining ligand (0.6 equiv.) added; stirred under O2-SO2 gas flow at room temp. for 2 h; flushed with O2 to remove SO2; H2O and MeOH added; kept for 48 h; recrystd. from CDCl3; ratio of the final compds. depended on react. microconditions; elem. anal.;A n/a
B 95%
chloroform-d1
865-49-6

chloroform-d1

C20H28AuOP
1428578-80-6

C20H28AuOP

C21H27AuCl3P
1428579-07-0

C21H27AuCl3P

Conditions
ConditionsYield
With triphenylphosphine95%
chloroform-d1
865-49-6

chloroform-d1

C19H33FN3Pd(1+)*CF3O3S(1-)
1571889-94-5

C19H33FN3Pd(1+)*CF3O3S(1-)

C19H33ClN3Pd(1+)*CF3O3S(1-)

C19H33ClN3Pd(1+)*CF3O3S(1-)

Conditions
ConditionsYield
at 80℃; for 9.5h; Inert atmosphere; Schlenk technique; Glovebox; Sealed tube;95%
[1-(2-Hex-1-ynyl-phenyl)-meth-(E)-ylidene]-phenyl-amine

[1-(2-Hex-1-ynyl-phenyl)-meth-(E)-ylidene]-phenyl-amine

chloroform-d1
865-49-6

chloroform-d1

C20H19(2)HCl3N
1028420-12-3

C20H19(2)HCl3N

Conditions
ConditionsYield
With 1,2-bis-(diphenylphosphino)ethane; bis-triphenylphosphine-palladium(II) chloride at 100℃;94%
chloroform-d1
865-49-6

chloroform-d1

([(i-Pr)2C3N2Me2]Ge(2,4,6-trimethylphenyl)2Et)I
1239426-13-1

([(i-Pr)2C3N2Me2]Ge(2,4,6-trimethylphenyl)2Et)I

chloro(ethyl)bis(2,4,6-trimethylphenyl)germanium
1239426-11-9

chloro(ethyl)bis(2,4,6-trimethylphenyl)germanium

Conditions
ConditionsYield
In chloroform-d1 (N2), Schlenk techniques; soln. of Ge compd. in CDCl3 stored for 10 min; extn. with satd. soln. of NH4Cl, aq. phase washed with CH2Cl2, combined org. phases dried over MgSO4, filtration, filtrate evapd., residue dissolved in hexanes, filtration through silica, evapn.;94%
chloro-trimethyl-silane
75-77-4

chloro-trimethyl-silane

chloroform-d1
865-49-6

chloroform-d1

A

tris(trimethylsilyl)deuteriomethane
65426-07-5

tris(trimethylsilyl)deuteriomethane

B

C7H19(2)HSi2
123145-84-6

C7H19(2)HSi2

Conditions
ConditionsYield
With 4,4'-di-tert-butylbiphenyl; lithium In tetrahydrofuran at -90 - -80℃;A 92%
B n/a
chloroform-d1
865-49-6

chloroform-d1

[(Ir(μ-pyrazolato)(H)(CN-t-Bu)2)2(μ-Cl)]CF3SO3
581797-57-1

[(Ir(μ-pyrazolato)(H)(CN-t-Bu)2)2(μ-Cl)]CF3SO3

[(Ir(μ-pyrazolato)(Cl)(CN-t-Bu)2)2(μ-Cl)]CF3SO3
581797-59-3

[(Ir(μ-pyrazolato)(Cl)(CN-t-Bu)2)2(μ-Cl)]CF3SO3

Conditions
ConditionsYield
In chloroform-d1 byproducts: CD2Cl2; Irradiation (UV/VIS); (Ar); Ir complex soln. irradiated in a sealed NMR tube with the direct sun light; layered with Et2O, crystd. for 2 d, filtered, washed (cold Et2O), dried (vac.); elem. anal.;90%
chloroform-d1
865-49-6

chloroform-d1

[W(CO)5(PH(CH(SiMe3)2)(OPh))]
1352656-20-2

[W(CO)5(PH(CH(SiMe3)2)(OPh))]

[W(CO)5(PCl(CH(SiMe3)2)(OPh))]
1416967-42-4

[W(CO)5(PCl(CH(SiMe3)2)(OPh))]

Conditions
ConditionsYield
With 12-crown-4, lithium diisopropylamide In diethyl ether under Ar, soln. of phosphane complex (0.1 mmol) and 12-crown-4 (0.1 mmol) in Et2O added dropwise to soln. of lithium diisopropylamide at -78°C, stirred for 0.5 h, solvent evapd. in vac., solid dissolved in CDCl3; volatiles evapd., residue washed with n-pentane at ca. -60°C, dried, crystd. from Et2O at ambient temp., detd. by 1H NMR, 13C NMR, 31P NMR, IR, MS, elem. anal., XRD;90%
chloroform-d1
865-49-6

chloroform-d1

(iPrP2SiH)Co(CO)2

(iPrP2SiH)Co(CO)2

(iPrP2SiCl)Co(CO)2

(iPrP2SiCl)Co(CO)2

Conditions
ConditionsYield
In chloroform-d1; benzene-d6 at 85℃; for 20h; Sealed tube; Inert atmosphere; Glovebox;90%
chloroform-d1
865-49-6

chloroform-d1

2-ethynylbenzaldehyde
38846-64-9

2-ethynylbenzaldehyde

aniline
62-53-3

aniline

C16H11(2)HCl3N

C16H11(2)HCl3N

Conditions
ConditionsYield
With 4 A molecular sieve In dichloromethane at 25℃; for 48h;89%
With MS4A at 20℃; for 48h;81%
chloromethyl(1,5-cyclooctadiene)palladium(II)

chloromethyl(1,5-cyclooctadiene)palladium(II)

chloroform-d1
865-49-6

chloroform-d1

((C6H5)2PCH2)2NC6H3(OH)COOH
909273-79-6

((C6H5)2PCH2)2NC6H3(OH)COOH

6Pd(2+)*6Cl(1-)*6((C6H5)2PCH2)2NC6H3(OH)COO(1-)*99C(2)HCl3=(PdCl(((C6H5)2PCH2)2NC6H3(OH)COO))6*99C(2)HCl3

6Pd(2+)*6Cl(1-)*6((C6H5)2PCH2)2NC6H3(OH)COO(1-)*99C(2)HCl3=(PdCl(((C6H5)2PCH2)2NC6H3(OH)COO))6*99C(2)HCl3

Conditions
ConditionsYield
In chloroform-d1 byproducts: CH4; ligand and Pd complex dissolved in CDCl3; stored for ca. 5 d; resultant Pd complex contained between 1 and 3 mol of CDCl3; ppt. isolated; elem. anal.; monitored by (1)H and (31)P NMR spectra;88%
chloroform-d1
865-49-6

chloroform-d1

dichlorofluoromethane-d
558-19-0

dichlorofluoromethane-d

Conditions
ConditionsYield
With antimony(III) fluoride; antimony pentafluoride at 35℃; for 4h;87%
chloroform-d1
865-49-6

chloroform-d1

Ir(CO)(H)2(C6H3(CH2P(CH(CH3)2)2)2)
193084-66-1, 193158-89-3

Ir(CO)(H)2(C6H3(CH2P(CH(CH3)2)2)2)

Ir(H)(Cl)(CO)(C6H3(CH2P(CH(CH3)2)2)2)
193084-78-5

Ir(H)(Cl)(CO)(C6H3(CH2P(CH(CH3)2)2)2)

Conditions
ConditionsYield
With triphenylphosphine In chloroform-d1 N2-atmosphere; room temp. (5 d); pptn. on pentane addn., washing (pentane);86.1%
dichloro bis(acetonitrile) palladium(II)
21264-30-2, 90243-59-7, 14592-56-4

dichloro bis(acetonitrile) palladium(II)

chloroform-d1
865-49-6

chloroform-d1

(E)-N,N'-dicyclohexyl-N-diphenylphosphino-4-acetamidine
1018686-28-6

(E)-N,N'-dicyclohexyl-N-diphenylphosphino-4-acetamidine

N,N'-dicyclohexyl-N-diphenylphosphino-acetamidine palladium dichloride*chloroform-d1
1018686-41-3

N,N'-dicyclohexyl-N-diphenylphosphino-acetamidine palladium dichloride*chloroform-d1

Conditions
ConditionsYield
In dichloromethane (N2); addn. of CH2Cl2 soln. of amidine deriv. to suspn. of palladium compd. in CH2Cl2, stirring for 18 h; evapn., washing with ether, dissolving in CDCl3, layering with hexane, keeping for 1 wk, isolation of crystals, elem. anal.;84%
2-ethyl-4,5-dihydrooxazole
10431-98-8

2-ethyl-4,5-dihydrooxazole

chloroform-d1
865-49-6

chloroform-d1

2-(trimethylsilyl)phenyl trifluoromethanesulfonate
88284-48-4

2-(trimethylsilyl)phenyl trifluoromethanesulfonate

C12H13(2)HCl3NO

C12H13(2)HCl3NO

Conditions
ConditionsYield
With potassium fluoride; 18-crown-6 ether at 60℃; for 12h; Inert atmosphere;80%
methyl 7β-[syn-2-(2-tritylaminothiazol-4-yl)-2-methoxyiminoacetamido]-3-acetoxymethyl-3-cephem-4-carboxylate

methyl 7β-[syn-2-(2-tritylaminothiazol-4-yl)-2-methoxyiminoacetamido]-3-acetoxymethyl-3-cephem-4-carboxylate

chloroform-d1
865-49-6

chloroform-d1

trimethylsilyl iodide
16029-98-4

trimethylsilyl iodide

Methyl 7β-[syn-2-(2-tritylaminothiazol-4-yl)-2-methoxyiminoacetamido]-3-iodomethyl-3-cephem-4-carboxylate

Methyl 7β-[syn-2-(2-tritylaminothiazol-4-yl)-2-methoxyiminoacetamido]-3-iodomethyl-3-cephem-4-carboxylate

Conditions
ConditionsYield
With sodium hydrogencarbonate; sodium hydrogensulfite76%
silver tetrafluoroborate
14104-20-2

silver tetrafluoroborate

chloroform-d1
865-49-6

chloroform-d1

1’-(diphenylphosphanyl)-1-cyanoferrocene

1’-(diphenylphosphanyl)-1-cyanoferrocene

[Ag(μ-1’-(diphenylphosphino)-1-cyanoferrocene)]2[BF4]2*0.1CHCl3

[Ag(μ-1’-(diphenylphosphino)-1-cyanoferrocene)]2[BF4]2*0.1CHCl3

Conditions
ConditionsYield
for 1h; Inert atmosphere; Darkness;76%
chloroform-d1
865-49-6

chloroform-d1

Cp(*)Ru[η(5)-CH2CHCHCHN(CMe3)]
222721-28-0

Cp(*)Ru[η(5)-CH2CHCHCHN(CMe3)]

A

Cp(*)Ru[η(4)-CH2=CHCH=CHNH(CMe3)]Cl
222721-22-4

Cp(*)Ru[η(4)-CH2=CHCH=CHNH(CMe3)]Cl

Cp(*)Ru[η(3)-CH2CHCHCH=N(CMe3)](Cl)2-syn-cis

Cp(*)Ru[η(3)-CH2CHCHCH=N(CMe3)](Cl)2-syn-cis

Cp(*)Ru[η(3)-CH2CHCHCH=N(CMe3)](Cl)2-syn-trans

Cp(*)Ru[η(3)-CH2CHCHCH=N(CMe3)](Cl)2-syn-trans

Conditions
ConditionsYield
In chloroform-d1 N2-atmosphere; 30 min; not isolated; detd. by (1)H NMR spectroscopy;A 12.5%
B 75%
C 12.5%
Grubbs catalyst first generation

Grubbs catalyst first generation

chloroform-d1
865-49-6

chloroform-d1

p-chlorophenyl isocyanide
1885-81-0

p-chlorophenyl isocyanide

[Ru(tricyclohexylphosphine)Cl2(p-chlorophenyl isocyanide)3]*CDCl3

[Ru(tricyclohexylphosphine)Cl2(p-chlorophenyl isocyanide)3]*CDCl3

Conditions
ConditionsYield
In benzene byproducts: PhCHP(C6H11)3; treatment of RuCl2(CHPh)(PCy3)2 with 3.3 equiv. of ClC6H4NC in benzene; crystn. from CDCl3 by slow diffusion of pentanes;75%

865-49-6Relevant academic research and scientific papers

Method for Small-Scale Production of Deuterochloroform

Tansukawat, Natha D.,See, Alyaa E.,Jiranuntarat, Sadudee,Corbin, Joshua R.,Schomaker, Jennifer M.

, p. 8739 - 8742 (2018)

Deuterochloroform (CDCl3) is a common deuterated solvent for nuclear magnetic resonance (NMR) analyses. The synthesis of significant amounts of CDCl3 for both research use and large undergraduate organic laboratories in a safe and in

H/D Exchange Reaction between CHCl3 and D2O in Two-Liquid-Phase System

Iwasaki, Matae,Sakka, Tetsuo,Ohashi, Shigeyuki,Matsushita, Hiroshi,Yokoyama, Atsushi,Suzuki, Kazuya

, p. 5139 - 5143 (1989)

The kinetics of hydrogen isotope exchange between CHCl3 and D2O has been studied by using a system which is composed of two liquid phases, a chloroform phase and an aqueous phase.The area of the interface between these two phases was kept constant (5.7 x 10-3 m2) during the reaction, where the reaction may be controlled by the interfacial transfer of chloroform.The isotopic content of chloroform in the chloroform phase was determined by an infrared absorption measurement.After the reaction, disappearance of deuteroxide ion was observed, which is caused by the chloroform hydrolysis reaction.The experimental results are reasonably explained on the basis of the model in which the reaction process is assumed to be composed of two steps: interfacial transfer of chloroform from the chloroform phase to the aqueous phase or vice versa, and the hydrogen isotope exchange reaction between CHCl3 and D2O in the aqueous phase.The rate constants for the interfacial transfer of chloroform and for the exchange reaction in the aqueous phase at 26.0 deg C were 0.107 +/- 0.003 m-2s-1 and 0.231 +/- 0.013 Lmol-1s-1, respectively.

A straightforward catalytic approach to obtain deuterated chloroform at room temperature

Higuera-Padilla, Angel Ruben,Kock, Flávio Vinícius Crizóstomo,Batista, Alzir Azevedo,Colnago, Luiz Alberto

, p. 917 - 920 (2020)

We report the catalytic activity for the complexes—cis-[RuCl2(dppb)(bipy)] (A), and [η6-(p-cymene)Ru (dppb)Cl]PF6 (B), wherein dppb = 1,4-bis(diphenylphosphine)butane, and bipy = 2,2′-bipyridine—for the synthesis of CDCl3 from CHCl3 using D2O as deuterium source. H/D exchange reactions were performed using a chloroform/D2O, 1:2 molar ratio, vigorously stirred, at room temperature. One mole of KOH was dissolved in D2O fraction and catalytic complexes from 0.002 to 0.05 mmol were dissolved in chloroform. The H/D exchange reactions were monitored using 13C nuclear magnetic resonance sequences without proton decoupling. The reaction using 0.01 mmol of compound A reached approximately 55percent of H/D conversion in 1 h. In the same time, the reactions with 0.002 mmol of compound A and without catalyst show approximately 28percent and 3percent H/D exchange, respectively. Without the catalysts, the H/D exchange was only 12.0percent in 5 h. For compound B, 55percent H/D conversion was observed in 1 h, only when 0.05 mmol was used, which is much higher catalyst concentration. After the isolation of the chloroform fraction and two more addition of D2O, it was possible to obtain 95.0percent H/D exchange in approximately 3 h, using 0.01 mmol of the compound A. Therefore, compound A is an efficient catalyst for a rapid and straightforward synthesis of CDCl3 from CHCl3 at room temperature and using D2O as deuterium source.

Novel chiral derivatizing reagent for the determination of enantiomeric excesses

-

, (2008/06/13)

A method for the determination of the enantiomeric composition of a chiral compound comprising (a) derivatising said chiral compound with a enantiomerically and diastereomerically pure compound of general formula I and (b) analysing the resulting mixture by an analytic technique. wherein Ar is an optionally substituted aromatic or heteroaromatic group.

Mechanisms and Products of Surface-Mediated Reductive Dehalogenation of Carbon Tetrachloride by Fe(II) on Goethite

Elsner, Martin,Haderlein, Stefan B.,Kellerhals, Thomas,Luzi, Samuel,Zwank, Luc,Angst, Werner,Schwarzenbach, Rene P.

, p. 2058 - 2066 (2008/12/21)

Aliphatic chlorinated hydrocarbons, including CCl4, are widespread groundwater contaminants. Mechanisms and product formation of CCl4 reduction by Fe(II) sorbed to goethite, which may lead to completely dehalogenated products or to form chloroform, a toxic product that is fairly persistent under anoxic conditions, were studied. A simultaneous transfer of two electrons and cleavage of two C-Cl bonds of CCl4 would completely circumvent chloroform production. Product formation pathways did not primarily depend on the competition between an initial one- and two-electron transfer, but on the presence of different radical scavengers and the properties of the mineral surface with respect to stabilization of reaction intermediates. Specific adsorption of major anions or pH effects could modify the capability of the goethite surface to stabilize short-lived radical intermediates.

Organophotoreceptor with a compound having a toluidine group

-

, (2008/06/13)

An improved organophotoreceptor comprises an electrically conductive substrate and a photoconductive element on the electrically conductive substrate wherein the photoconductive element comprisesa) a charge transport material with the following formula where R1 and R2 are, independently, a carbazolyl group, an (N,N-disubstituted) aminoaryl group, such as a triphenyl amine group, or a julolidine group, and R3 and R4 are, independently, hydrogen, branched or linear alkyl group (e.g., a C1-C20 alkyl group), branched or linear unsaturated hydrocarbon group, cycloalkyl group (e.g. cyclohexyl group), or aryl group (e.g., phenyl group, naphthyl group, stilbenyl group, (9H-fluoren-9-ylidene)benzyl group, or tolanyl group);(b) an optional charge transport compound; and(c) a charge generating compound.

BENZOXAZOLE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND HERBICIDE

-

, (2008/06/13)

The present invention relates to benzoxazole compounds represented by the following formula (I): wherein R1 to R4 may be the same or different from each other, and each represent a hydrogen atom, alkyl group having 1 to 6 carbon atoms, alkoxy group having 1 to 4 carbon atoms, haloalkyl group having 1 to 4 carbon atoms, haloalkoxy group having 1 to 4 carbon atoms, halogen atom, nitro group, cyano group, R12S(O)n, alkoxycarbonyl group having 1 to 4 carbon atoms, amino group, -NHCOR11 or carbonyl group, where R11 and R12 each represent an alkyl group having 1 to 6 carbon atoms, and n is an integer of 0 to 2, A represents a single bond, CHR5-Y, CR5=CR6, CR5R7-CHR6 or CHR5, where R5 represents a hydrogen atom, hydroxyl group, halogen atom or alkyl group, R6 and R7 each represent a hydrogen atom, hydroxyl group, alkyl group, halogen atom or substituted sulfonyloxy group, Y represents O, S or NH, and W represents a substituted or unsubstituted benzene ring or hetero ring, and processes for preparing the same.

Substituted tetrahydronaphthaline and analogous compounds

-

, (2008/06/13)

Substituted tetrahydro-naphthalenes and analogous compounds are prepared by reducing or condensing appropriate functional substituents in substituted tetrahydro-naphthalenes and analogous compounds by customary methods and converting functional groups in this manner into the desired groups. The compounds according to the invention are suitable for use as active compounds in pharmaceuticals, in particular in pharmaceuticals for treating arteriosclerosis and also dyslipidaemias.

Chemokine receptor antagonists and methods of use therefor

-

, (2008/06/13)

Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: and physiologically acceptable salts thereof.

Solvent-free mechanochemical preparation of phosphonium salts, phosphorus ylides, and olefins

-

, (2008/06/13)

The present invention provides a method of preparing a phosphonium salt of the formula [R1R2R3P—CR4R5R6]X, comprising ball-milling a phosphine of the formula R1R2R3P with a compound of the formula XCR4R5R6; a method of preparing a phosphorus ylide of the formula R1R2R3P═CR4R5, comprising ball-milling a phosphonium salt of the formula [R1R2R3P—HCR4R5]X in the presence of a base; and a method of preparing an olefin of the formula R4R5C═CR7H or R4R5C═CR7R8, comprising ball-milling a phosphorus ylide of the formula R1R2R3P═CR4R5 with a compound of the formula R7C(O)H or R7C(O)R8. The inventive method produces phosphonium salts and phosphorus ylides by mechanical processing solid reagents under solvent-free conditions. The advantages of the present invention over conventional solution methods, include: (1) extremely high selectivity; (2) high yields; (3) low processing temperatures; (4) simple and scalable reactions using commercially available equipment; and (5) the complete elimination of solvents from the reaction.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 865-49-6